ZA958946B - Use of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta A4 formation in alzheimer's disease - Google Patents

Use of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta A4 formation in alzheimer's disease

Info

Publication number
ZA958946B
ZA958946B ZA958946A ZA958946A ZA958946B ZA 958946 B ZA958946 B ZA 958946B ZA 958946 A ZA958946 A ZA 958946A ZA 958946 A ZA958946 A ZA 958946A ZA 958946 B ZA958946 B ZA 958946B
Authority
ZA
South Africa
Prior art keywords
alpha
alzheimer
disease
pct
acetonitrile
Prior art date
Application number
ZA958946A
Other languages
English (en)
Inventor
Roger Edward Markwell
Julie Hawkins
Carol Wendy Gray
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ZA958946B publication Critical patent/ZA958946B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA958946A 1994-10-25 1995-10-23 Use of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta A4 formation in alzheimer's disease ZA958946B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods

Publications (1)

Publication Number Publication Date
ZA958946B true ZA958946B (en) 1996-08-20

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA958946A ZA958946B (en) 1994-10-25 1995-10-23 Use of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta A4 formation in alzheimer's disease

Country Status (22)

Country Link
US (1) US5891887A (ko)
EP (1) EP0786998B1 (ko)
JP (1) JPH10509697A (ko)
KR (1) KR100393365B1 (ko)
CN (1) CN1085529C (ko)
AT (1) ATE214926T1 (ko)
AU (1) AU698695B2 (ko)
BG (1) BG101500A (ko)
BR (1) BR9509433A (ko)
CZ (1) CZ287370B6 (ko)
DE (1) DE69526102T2 (ko)
DK (1) DK0786998T3 (ko)
ES (1) ES2173977T3 (ko)
GB (1) GB9421472D0 (ko)
HK (1) HK1002057A1 (ko)
HU (1) HUT77007A (ko)
NO (1) NO312055B1 (ko)
NZ (1) NZ295155A (ko)
PT (1) PT786998E (ko)
SK (1) SK50497A3 (ko)
WO (1) WO1996012486A1 (ko)
ZA (1) ZA958946B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
WO1999045924A1 (en) 1998-03-11 1999-09-16 Smithkline Beecham Plc Composition
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269330T1 (de) * 1989-04-13 2004-07-15 Beecham Group Plc Chemische verbindungen
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
HK1002057A1 (en) 1998-07-31
EP0786998A1 (en) 1997-08-06
KR100393365B1 (ko) 2003-12-18
PT786998E (pt) 2002-09-30
BR9509433A (pt) 1997-09-16
DE69526102T2 (de) 2002-10-31
US5891887A (en) 1999-04-06
NZ295155A (en) 2000-07-28
AU698695B2 (en) 1998-11-05
KR970706816A (ko) 1997-12-01
CZ287370B6 (en) 2000-11-15
NO971899L (no) 1997-04-24
NO971899D0 (no) 1997-04-24
JPH10509697A (ja) 1998-09-22
AU3843195A (en) 1996-05-15
DE69526102D1 (de) 2002-05-02
ATE214926T1 (de) 2002-04-15
DK0786998T3 (da) 2002-07-15
ES2173977T3 (es) 2002-11-01
WO1996012486A1 (en) 1996-05-02
HUT77007A (hu) 1998-03-02
CN1170365A (zh) 1998-01-14
GB9421472D0 (en) 1994-12-07
EP0786998B1 (en) 2002-03-27
CN1085529C (zh) 2002-05-29
MX9703077A (es) 1997-07-31
CZ125197A3 (en) 1997-07-16
NO312055B1 (no) 2002-03-11
SK50497A3 (en) 1997-09-10
BG101500A (en) 1998-01-30

Similar Documents

Publication Publication Date Title
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
IL107495A0 (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
EP1014996A4 (en) SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS
CA2351617A1 (en) Method for inhibiting dental resorptive lesions
PL309594A1 (en) Apllication of rilusole in treating parkinson disease and parkinsonian syndromes
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
HK1002057A1 (en) Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease
ZA974387B (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases.
HUP9904401A2 (hu) [R-(Z)]-alfa-(Metoxi-imino)-alfa-(1-aza-biciklo[2.2.2]okt-3-il)-acetonitril-monohidroklorid hatóanyag-tartalmú szabályozott kibocsátású dózisforma
IL112288A (en) Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
HUP0103149A2 (hu) Gyógyszerkészítmény Alzheimer-kór kezelésére
ZA933567B (en) Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease
English et al. Recurrent suppurative thyroiditis due to pyriform fossa—thyroid fistula
Carbon Effectiveness of moxalactam in septicemias and focal infections. Results of the cooperative study carried out in France.
IL153003A0 (en) Medicaments for treating colics
YU9302A (sh) Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa